Neptune Krill Oil Certified as “Friend of the Sea

Neptune Technologies & Bioressources Inc. (“Neptune”) is proud to announce that it has been certified as a “Friend of the Sea”.
Neptune engaged in a certification process with Friends of the Sea (‘‘FOS’’), an internationally recognized organization which verifies the sustainable origin of marine products. FOS has been selected by Omega-3 producers worldwide as the most independent and reliable sustainability certification. The eco-label also provides an effective way to communicate environmental performance to their customers.

Neptune successfully obtained FOS certification by complying with strict krill sustainability criteria which ensure that the stock is not overfished, the fishery is in compliance with the management measures, there’s no bycatch of endangered species, there is no adverse impact on the ecosystem or seabed. Furthermore Neptune was found also to fulfill social accountability requirements and the gradual reduction of carbon footprint.

This certification can also be extended to distributors who can successfully substantiate that Neptune is their sole krill oil provider. Once audited, it will allow them to include the FOS logo on their packaging and marketing material. The FOS claim is very straight forward and easily understood by consumers compared to other sustainability certifications.

In conjunction, with the NSF accreditation obtained in 2011, Neptune has ensured an environmentally responsible business approach from sourcing of raw material to commercialization.
“We are proud to be partner with an exceptional figure representing a strong and strategic organization with the environment’s well-being as its primary mission” added Wael Massrieh, Vice-President, Scientific Affairs.

For more information please contact:
Paolo Bray – Director
Friend of the Sea

Neptune Technologies & Bioressources Inc.
André Godin, CFO

Howard Group
Dave Burwell
(888) 221-0915

Friend of the Sea
Friend of the Sea is an international non-profit certification scheme for products from sustainable fisheries and aquaculture. Certified products are fished from not overexploited nor IUCN Redlisted stocks and with selective methods which do not impact the seabed.

Neptune Technologies & Bioressources Inc.
Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune’s products are marketed and distributed in over 30 countries worldwide.

Acasti Pharma Inc.
Acasti Pharma (TSXV: APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

Share On Twitter